Physician profile
Julia Elrod
NPI 1588327878
$3,466.89
in general payments reported to CMS, 2019-2025
22 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $154 · 2024: $1,531 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.85 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.49 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.61 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $307.71 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $305.63 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $218.45 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $138.30 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $133.50 | 2022-2025 | Trintellix, Gattex |
| Boston Scientific Corporation | $131.76 | 2025 | Watchman Flx |
| Alkermes, INC. | $128.56 | 2024 | Lybalvi, Vivitrol |
| Gilead Sciences, INC. | $124.74 | 2024 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $124.64 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $93.61 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $92.58 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.90 | 2024-2025 | Jardiance |
| Dexcom, INC. | $59.93 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $51.39 | 2025 | Sublocade |
| Regeneron Healthcare Solutions, INC. | $41.26 | 2022 | |
| Medtronic, INC. | $37.81 | 2025 | Minimed 780g |
| Axsome Therapeutics, INC. | $37.64 | 2025 | Auvelity |
| Biomerieux INC | $23.40 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Lundbeck LLC | $21.93 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $17.05 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Elrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.